Our results also showed that RBM39 expression was positively correlated with the expression levels of immune checkpoint genes in four types of cancer, suggesting that RBM39 may regulate tumour immune patterns through the number of tumours neoantigens and by regulating the expression levels of immune checkpoint genes. The gene discussed is RBM39; the disease is cancer.